BFM
PCVX icon

Boothbay Fund Management’s Vaxcyte PCVX Stock Holding History

Boothbay Fund Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.7M Buy
614,600
+413,300
+205% +$22.4M 0.47% 21
2026
Q1 		$11.7M Buy
+201,300
New +$10.9M 0.15% 111
2024
Q4 		– Sell
-3,600
Closed -$411K – 1817
2024
Q3 		$411K Buy
+3,600
New +$324K 0.01% 1070

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Boothbay Fund Management's PCVX Position: Q2 2026 in Review

Boothbay Fund Management increased its Vaxcyte (PCVX) stake by 2.3% in Q2 2026, buying an estimated $660K and bringing the position to 534,163 shares worth $31.1M. The position accounts for 0.41% of the portfolio, ranked #26.

Boothbay Fund Management first reported a position in PCVX in Q2 2020 and has held it in 18 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Boothbay Fund Management held 534,163 shares of Vaxcyte worth $31.1M as of Q2 2026.
  • Boothbay Fund Management bought 12,144 Vaxcyte shares in Q2 2026, an estimated $660K.
  • Vaxcyte made up 0.41% of Boothbay Fund Management's portfolio in Q2 2026, its #26 holding.
  • Boothbay Fund Management first reported a position in Vaxcyte in Q2 2020 and has held it in 18 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.